NCT07112170Recruiting
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma (CURB-Melanoma) - a Phase 2 Clinical Trial
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 29 Jul 2025
- Start date
- 24 Jul 2025
- Primary completion date
- 24 Jul 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Melanoma
- NCT number
- NCT07112170
What you commit to
- Study type: Interventional
- Planned participants: 52
- From 24 Jul 2025 to the primary completion date, 24 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia or scleroderma.
- Prior radiotherapy near the oligoprogressive lesion precluding SBRT or hypofractionated radiotherapy due to exceeding OAR tolerance.
Other illness
- \>10 extracranial sites of progressive disease.
- Leptomeningeal disease.
- Any other condition which in the judgment of the investigator would make the patient inappropriate for entry into this study.
Other
- Pregnancy.
- Any psychological, sociological or geographical issue potentially hampering compliance with the study.
Who the study is looking for
- Age 18 or older
- ECOG 0-2
- Willing and able to provide informed consent
- Metastatic melanoma detected on imaging and clinically confirmed.
- Treated with first line immunotherapy or BRAF inhibitors.
- No upper limit to the number of total metastatic sites, but a maximum of ten progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extra cranial.
- Patients who had any prior radiation therapy near or overlapping with the oligoprogressive sites are allowed to enroll.
- All sites of oligoprogression that can be safely treated with SBRT or hypofractionated radiotherapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Health Network Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.